2023
The Impact of Racial Disparities on Outcome in Patients With Stage IIIC Endometrial Carcinoma
Patrich T, Wang Y, Elshaikh M, Zhu S, Damast S, Li J, Fields E, Beriwal S, Keller A, Kidd E, Usoz M, Jolly S, Jaworski E, Leung E, Taunk N, Chino J, Russo A, Lea J, Lee L, Albuquerque K, Hathout L. The Impact of Racial Disparities on Outcome in Patients With Stage IIIC Endometrial Carcinoma. American Journal Of Clinical Oncology 2023, 46: 114-120. PMID: 36625449, DOI: 10.1097/coc.0000000000000975.Peer-Reviewed Original ResearchMeSH KeywordsChemotherapy, AdjuvantEndometrial NeoplasmsFemaleHumansLymph NodesNeoplasm StagingRetrospective StudiesConceptsStage IIIC endometrial carcinomaRecurrence-free survivalNon-black patientsParaaortic lymph nodesGrade 3 tumorsBlack patientsOverall survivalEndometrial carcinomaWorse OSLymph nodesNonendometrioid histologyPositive paraaortic lymph nodesRetrospective multi-institutional studyKaplan-Meier methodMulti-institutional studySPSS version 27Adjuvant chemotherapyConcurrent chemoradiotherapyHazard ratioRFS ratesClinical outcomesRandomized trialsNonsignificant trendPatientsPrognostic covariates
2022
An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva
Li JY, Arkfeld CK, Tymon-Rosario J, Webster E, Schwartz P, Damast S, Menderes G. An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva. Journal Of Gynecologic Oncology 2022, 33: 0. PMID: 34910394, PMCID: PMC8899873, DOI: 10.3802/jgo.2022.33.e13.Peer-Reviewed Original ResearchConceptsDisease-specific survivalSquamous cell carcinomaOverall survivalPositive marginsCell carcinomaNodal involvementPrognostic factorsStage IFive-year disease-specific survivalPrimary squamous cell carcinomaRecurrent squamous cell carcinomaFive-year RFSNode-positive patientsVulvar cancer patientsEscalation of treatmentConservative surgical approachKaplan-Meier estimatesLog-rank testCox proportional hazardsLocal RFSOverall RFSAdjuvant radiotherapyDistant recurrenceFree survivalMedian survival
2021
Does Prophylactic Paraortic Lymph Node Irradiation Improve Outcomes in Women With Stage IIIC1 Endometrial Carcinoma?
Yoon J, Fitzgerald H, Wang Y, Wang Q, Vergalasova I, Elshaikh MA, Dimitrova I, Damast S, Li JY, Fields EC, Beriwal S, Keller A, Kidd EA, Usoz M, Jolly S, Jaworski E, Leung EW, Donovan E, Taunk NK, Chino J, Natesan D, Russo AL, Lea JS, Albuquerque KV, Lee LJ, Hathout L. Does Prophylactic Paraortic Lymph Node Irradiation Improve Outcomes in Women With Stage IIIC1 Endometrial Carcinoma? Practical Radiation Oncology 2021, 12: e123-e134. PMID: 34822999, DOI: 10.1016/j.prro.2021.10.002.Peer-Reviewed Original ResearchMeSH KeywordsEndometrial NeoplasmsFemaleHumansLymph NodesNeoplasm Recurrence, LocalNeoplasm StagingRadiotherapy, AdjuvantRetrospective StudiesConceptsStage IIIC1 endometrial cancerPelvic radiation therapyOverall survivalEndometrial cancerRadiation therapySurvival outcomesFirst recurrenceHazard ratioRFS ratesCommon siteRecurrence-free survival ratesMulti-institutional retrospective studyPropensity scoreCox proportional hazards modelImproved survival outcomesKaplan-Meier methodProportional hazards modelInternational FederationNew therapeutic approachesAdjuvant chemotherapyDistant recurrenceSystemic chemotherapyImprove OutcomesClinical outcomesDistant metastasisPrognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy
Li JY, Park HS, Huang GS, Young MR, Ratner E, Santin A, Damast S. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. Gynecologic Oncology 2021, 163: 557-562. PMID: 34602287, DOI: 10.1016/j.ygyno.2021.09.018.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalEndometrioid endometrial cancerVaginal brachytherapyPMMR patientsOverall survivalEEC patientsEndometrial cancerExact testThree-year recurrence-free survivalEarly-stage endometrial cancerCox proportional hazards regressionPoor recurrence-free survivalAdjuvant vaginal brachytherapyThree-year OSMultivariable Cox regressionLympho-vascular invasionSignificant prognostic variablesProportional hazards regressionLog-rank testKaplan-Meier estimatesDeficient mismatch repairMismatch repair statusFisher's exact testMismatch repair deficiencyDMMR statusA Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer
Hathout L, Wang Y, Wang Q, Vergalasova I, Elshaikh MA, Dimitrova I, Damast S, Li JY, Fields EC, Beriwal S, Keller A, Kidd EA, Usoz M, Jolly S, Jaworski E, Leung EW, Donovan E, Taunk NK, Chino J, Natesan D, Russo AL, Lea JS, Albuquerque KV, Lee LJ. A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 110: 1423-1431. PMID: 33677053, DOI: 10.1016/j.ijrobp.2021.02.055.Peer-Reviewed Original ResearchConceptsStage IIIC endometrial carcinomaOverall survivalEndometrial carcinomaRadiation therapyAdjuvant chemotherapyAdjuvant therapyPALN recurrenceSystemic chemotherapyRFS ratesMulti-institutional retrospective cohort studyStage IIIC endometrial cancerRecurrence-free survival ratesLymph node recurrenceSequential radiation therapyAdjuvant radiation therapyRetrospective cohort studyGrade 3 tumorsAdjuvant treatment regimensKaplan-Meier methodVaginal cuff brachytherapyHigh rateSequence of treatmentChemotherapy concurrentNodal radiationNode recurrenceBenefits of a Multidisciplinary Women’s Sexual Health Clinic in the Management of Sexual and Menopausal Symptoms After Pelvic Radiotherapy
Li JY, D’Addario J, Tymon-Rosario J, Menderes G, Young MR, Johung K, Ratner E, Minkin MJ, Damast S. Benefits of a Multidisciplinary Women’s Sexual Health Clinic in the Management of Sexual and Menopausal Symptoms After Pelvic Radiotherapy. American Journal Of Clinical Oncology 2021, 44: 143-149. PMID: 33755031, DOI: 10.1097/coc.0000000000000800.Peer-Reviewed Original ResearchMeSH KeywordsAdultBrachytherapyCombined Modality TherapyDyspareuniaFemaleGenital Neoplasms, FemaleHumansInterdisciplinary CommunicationMenopauseMiddle AgedPatient SatisfactionPelvisRadiation InjuriesRadiotherapyRectal NeoplasmsRetrospective StudiesSexual Dysfunction, PhysiologicalSexual HealthTreatment OutcomeVaginal DiseasesWomen's Health ServicesConceptsPelvic radiotherapySexual health clinicsMenopausal symptomsPersistent menopausal symptomsSystemic hormone therapyFemale cancer patientsPatterns of careDilator therapyVaginal estrogenGastrointestinal malignanciesHormone therapyVaginal drynessMedian ageMultidisciplinary careRetrospective reviewFemale patientsTreatment patternsCancer patientsPatient satisfactionSexual symptomsTestosterone creamVaginal lubricantsHealth clinicsSTATA 13.1Patients
2020
Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study
Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, Fader AN. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecologic Oncology 2020, 159: 17-22. PMID: 32709539, PMCID: PMC7541557, DOI: 10.1016/j.ygyno.2020.07.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorChemoradiotherapy, AdjuvantCystadenocarcinoma, SerousFemaleFollow-Up StudiesHumansHysterectomyImmunohistochemistryMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPrognosisProgression-Free SurvivalReceptor, ErbB-2Retrospective StudiesRisk AssessmentUnited StatesUterine NeoplasmsUterusConceptsHuman epidermal growth factor 2Uterine serous carcinomaHER2-positive tumorsEarly-stage diseaseOverall survivalSerous carcinomaCohort studyHER2 positivityPositive tumorsEarly stage uterine serous carcinomaLymph-vascular space invasionRecurrent uterine serous carcinomaMulti-institutional cohort studyHuman epidermal growth factor receptor 2Multi-center cohort studyEpidermal growth factor receptor 2Epidermal growth factor 2HER2-positive cohortGrowth factor receptor 2HER2-negative tumorsEquivocal IHC resultsFactor receptor 2Inferior PFSAdjuvant therapyGrowth factor 2Stage III uterine serous carcinoma: modern trends in multimodality treatment
Li JY, Young MR, Huang G, Litkouhi B, Santin A, Schwartz PE, Damast S. Stage III uterine serous carcinoma: modern trends in multimodality treatment. Journal Of Gynecologic Oncology 2020, 31: e53. PMID: 32266802, PMCID: PMC7286763, DOI: 10.3802/jgo.2020.31.e53.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyEndometrial NeoplasmsFemaleHumansHysterectomyMiddle AgedNeoplasm StagingRadiotherapy, AdjuvantRetrospective StudiesConceptsUterine serous carcinomaExternal beam RTVaginal brachytherapyOverall survivalHuman epidermal growth factor receptorModern treatment eraSentinel node samplingRegional nodal recurrenceKaplan-Meier estimatesLog-rank testCox proportional hazardsExternal beam radiotherapyEpidermal growth factor receptorERA treatmentGrowth factor receptorUSC patientsFree survivalNodal recurrenceTreatment eraMultimodality treatmentPatient characteristicsPerioperative periodRegional nodalSerous carcinomaNode sampling
2019
Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy
Hochreiter A, Kelly JR, Young MR, Litkouhi B, Black JD, Stromberger C, Higgins S, Schwartz PE, Damast S. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy. International Journal Of Gynecological Cancer 2019, 30: 48. PMID: 31722964, DOI: 10.1136/ijgc-2019-000675.Peer-Reviewed Original ResearchConceptsDisease-free survivalLower uterine segment involvementPelvic recurrence-free survivalStage IB grade 2Uterine segment involvementLymph node dissectionRecurrence-free survivalEndometrial cancerRisk factorsVaginal brachytherapyOverall survivalGrade 2Endometrioid histologyNode dissectionPelvic recurrenceSegment involvementLymph nodesMyometrial invasionMultivariable Cox proportional hazards regressionEarly-stage endometrial cancerUnderwent lymph node dissectionCox proportional hazards regressionReduced disease-free survivalAdjuvant vaginal brachytherapySole adjuvant therapy
2015
Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer
Gressel GM, Lundsberg LS, Altwerger G, Katchi T, Azodi M, Schwartz PE, Ratner ES, Damast S. Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer. International Journal Of Gynecological Cancer 2015, 25: 1711-1716. PMID: 26332394, PMCID: PMC4623851, DOI: 10.1097/igc.0000000000000554.Peer-Reviewed Original ResearchConceptsBrain metastatic diseaseEpithelial ovarian cancerBrain metastasesEndometrial cancerCervical cancerGynecologic cancerSurgical resectionTwo-year overall survival ratesLargest single-institution experienceSingle institution experienceOverall survival rateOverall survival dataMedian survival timeSignificant hazard ratioLong-term survivalHazard ratioMetastatic diseaseOverall survivalImproved survivalRetrospective reviewIntracranial metastasesPalliative carePoor prognosisCancer increasesFactors Predictive
2014
Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer: Analysis of Outcomes and Patterns of Recurrence Based on Pathologic Characteristics
Young MR, Higgins SA, Ratner E, Yu JB, Mani S, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Damast S. Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer: Analysis of Outcomes and Patterns of Recurrence Based on Pathologic Characteristics. International Journal Of Gynecological Cancer 2014, 25: 431. PMID: 25621409, PMCID: PMC5603450, DOI: 10.1097/igc.0000000000000376.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyCarboplatinChemoradiotherapy, AdjuvantDisease-Free SurvivalEndometrial NeoplasmsFemaleHumansHysterectomyLymph NodesLymphatic MetastasisMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPaclitaxelRetrospective StudiesSurvival RateTreatment FailureConceptsDisease-free survivalVaginal cuff brachytherapyStage III endometrial adenocarcinomaStage III endometrial cancerNode-negative diseaseOverall survivalAdjuvant chemotherapyEndometrial cancerEndometrial adenocarcinomaType IComprehensive surgical stagingLow-risk histologyNode-positive diseaseOutcomes of patientsHigh-risk histologyNode-positive ratePatterns of recurrenceAnalysis of outcomesType II diseaseAdjuvant carboplatinVaginal failuresSurgical stagingAdjuvant therapyNode negativeNode positive
2012
Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I–II papillary serous endometrial cancer
Kiess AP, Damast S, Makker V, Kollmeier MA, Gardner GJ, Aghajanian C, Abu-Rustum NR, Barakat RR, Alektiar KM. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I–II papillary serous endometrial cancer. Gynecologic Oncology 2012, 127: 321-325. PMID: 22850412, DOI: 10.1016/j.ygyno.2012.07.112.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyCarboplatinChemoradiotherapy, AdjuvantCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousDrug Administration ScheduleEndometrial NeoplasmsFemaleFollow-Up StudiesHumansHysterectomyMiddle AgedNeoplasm StagingOvariectomyPaclitaxelRetrospective StudiesSalpingectomySurvival AnalysisTreatment OutcomeConceptsCarboplatin/paclitaxel chemotherapyUterine papillary serous carcinomaPaclitaxel chemotherapyStage IEarly-stage uterine papillary serous carcinomaPapillary serous endometrial cancerParaaortic lymph node samplingDistant recurrence ratesMedian patient ageStage II diseaseFive-year outcomesLymph node samplingKaplan-Meier methodOverall survival ratePapillary serous carcinomaSingle institution experienceLog-rank testSerous endometrial cancerConcurrent carboplatinMedian followPelvic radiationOmental biopsyPara-aorticPelvic recurrenceUnderwent surgery
2009
Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era
Damast S, Ho AY, Montgomery L, Fornier MN, Ishill N, Elkin E, Beal K, McCormick B. Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era. International Journal Of Radiation Oncology • Biology • Physics 2009, 77: 1105-1112. PMID: 19879068, DOI: 10.1016/j.ijrobp.2009.06.042.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCapecitabineCarboplatinCyclophosphamideDeoxycytidineDisease-Free SurvivalDose Fractionation, RadiationDoxorubicinDrug Administration ScheduleEpirubicinFemaleFluorouracilHumansMastectomy, Modified RadicalMiddle AgedNeoadjuvant TherapyPaclitaxelRadiodermatitisRadiotherapy, AdjuvantRetrospective StudiesConceptsDistant metastasis-free survivalStandard fractionation radiationCombined-modality therapyInflammatory breast cancer patientsMetastasis-free survivalBreast cancer patientsLocoregional controlRadiation therapyLocoregional outcomeSkin bolusCancer patientsChest wallAdjuvant radiation therapyExcellent locoregional controlMajority of patientsSignificant therapeutic challengeScar boostTaxane eraIBC patientsRadical mastectomyRegional lymphaticsTherapeutic challengeDaily fractionsStandard fractionationPrescribed treatment